BioNTech SE (ETR:22UA)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of EUR 20.20 billion. The enterprise value is 7.02 billion.

Market Cap	20.20B
Enterprise Value	7.02B

Important Dates

The last earnings date was Tuesday, May 5, 2026.

Earnings Date	May 5, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.91%
Shares Change (QoQ)	+3.81%
Owned by Insiders (%)	16.73%
Owned by Institutions (%)	20.08%
Float	109.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.20
PB Ratio	1.08
P/TBV Ratio	1.20
P/FCF Ratio	31.93
P/OCF Ratio	24.77
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-5.61
EV / Sales	2.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	11.09

Financial Position

The company has a current ratio of 8.80, with a Debt / Equity ratio of 0.02.

Current Ratio	8.80
Quick Ratio	8.11
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	0.48
Interest Coverage	-97.41

Financial Efficiency

Return on equity (ROE) is -6.66% and return on invested capital (ROIC) is -25.58%.

Return on Equity (ROE)	-6.66%
Return on Assets (ROA)	-4.18%
Return on Invested Capital (ROIC)	-25.58%
Return on Capital Employed (ROCE)	-7.31%
Weighted Average Cost of Capital (WACC)	11.67%
Revenue Per Employee	359,319
Profits Per Employee	-160,395
Employee Count	7,807
Asset Turnover	0.13
Inventory Turnover	3.34

Taxes

In the past 12 months, BioNTech SE has paid 78.70 million in taxes.

Income Tax	78.70M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -9.98% in the last 52 weeks. The beta is 1.37, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.37
52-Week Price Change	-9.98%
50-Day Moving Average	81.94
200-Day Moving Average	87.57
Relative Strength Index (RSI)	39.90
Average Volume (20 Days)	67,842

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.95

Income Statement

In the last 12 months, BioNTech SE had revenue of EUR 2.81 billion and -1.25 billion in losses. Loss per share was -5.11.

Revenue	2.81B
Gross Profit	2.21B
Operating Income	-1.41B
Pretax Income	-1.17B
Net Income	-1.25B
EBITDA	-1.19B
EBIT	-1.41B
Loss Per Share	-5.11

Balance Sheet

The company has 13.71 billion in cash and 302.80 million in debt, with a net cash position of 13.40 billion.

Cash & Cash Equivalents	13.71B
Total Debt	302.80M
Net Cash	13.40B
Net Cash Per Share	n/a
Equity (Book Value)	18.70B
Book Value Per Share	73.94
Working Capital	13.77B

Cash Flow

In the last 12 months, operating cash flow was 815.70 million and capital expenditures -183.00 million, giving a free cash flow of 632.70 million.

Operating Cash Flow	815.70M
Capital Expenditures	-183.00M
Depreciation & Amortization	221.10M
Net Borrowing	-10.70M
Free Cash Flow	632.70M
FCF Per Share	n/a

Margins

Gross margin is 78.65%, with operating and profit margins of -50.35% and -44.64%.

Gross Margin	78.65%
Operating Margin	-50.35%
Pretax Margin	-41.83%
Profit Margin	-44.64%
EBITDA Margin	-42.47%
EBIT Margin	-50.35%
FCF Margin	22.55%

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.91%
Shareholder Yield	-1.91%
Earnings Yield	-6.20%
FCF Yield	3.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 7.3 and a Piotroski F-Score of 3.

Altman Z-Score	7.3
Piotroski F-Score	3